ENA Respiratory is a clinical-stage pharmaceutical company developing innate immune modulators administered as convenient, self-administrated nasal products for the prevention of complications resulting from respiratory viral infections in populations at risk due to:
- age (60 years old and over);
- underlying medical conditions, or
- occupational risk
The ENA team has a long history of successful drug development in respiratory diseases and seeks to leverage this expertise to meet the considerable unmet need that still exists for these vulnerable populations.
At-Risk Populations Due to Comorbid Conditions
- COPD, Asthma
- Congestive Heart Failure
- Chronic Kidney Disease
- Lymphoma/Chronic Leukemia
- High-Dose Corticosteroids
At Risk Occupations
- Healthcare workers
- Transportation workers
- Military Personnel
Headquartered in Melbourne Australia, the company has secured a Series A investment.
In 2022, ENA Respiratory was selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and U.S. BARDA.
In 2022, ENA Respiratory partnered with the US-based COPD Foundation to accelerate the clinical development of INNA-051 in COPD through its access to patients, a global network of accredited centres, scientific expertise, and patient investigators.
U.S. Department of Defense
In 2023, ENA Respiratory was awarded a USD8.18 million contract from the U.S. Department of Defense to support the ongoing development of INNA-051.